Anuh Pharma
71.22
-1.56(-2.14%)
Market Cap₹713.80 Cr
PE Ratio18.96
IndustryHealthcare
Company Performance:
1D-2.14%
1M-9.10%
6M-24.50%
1Y-31.06%
5Y-36.09%
View Company Insightsright
More news about Anuh Pharma
15Jul 25
Anuh Pharma Boosts Production Capacity with New Manufacturing Facility in Tarapur
Anuh Pharma Limited has inaugurated a new manufacturing facility, Manufacturing Block INT-1A, in Tarapur, Maharashtra. The facility, opened on July 15, 2025, will increase the company's production capacity by 200 MT/Annum, bringing the total to approximately 2,400 MT/Annum. The expansion includes an additional 40 KL of reactor capacity, enhancing the company's infrastructure to meet growing market demands in the pharmaceutical sector.
23May 25
Anuh Pharma Reports Mixed Q4 Results, Recommends Dividend
Anuh Pharma Ltd. released its Q4 FY2023-24 results, showing a 15.85% increase in revenue to ₹1,900 crore. However, net profit declined by 18.62% to ₹125 crore. The company's EBITDA margin contracted to 10.48%. Despite Q4 challenges, annual performance for FY2024 was strong with a 23.52% revenue growth and 66.02% increase in net profit. The board recommended a dividend of ₹1.50 per equity share.
Anuh Pharma
71.22
-1.56
(-2.14%)
1 Year Returns:-31.06%
Industry Peers
Sun Pharmaceutical
1,612.90
(-0.06%)
Divis Laboratories
6,010.00
(-0.05%)
Torrent Pharmaceuticals
3,981.80
(+0.13%)
Cipla
1,369.60
(-0.64%)
Lupin
2,140.70
(-1.27%)
Dr Reddys Laboratories
1,157.20
(-0.81%)
Zydus Life Science
876.25
(+0.33%)
Mankind Pharma
2,099.10
(-1.19%)
Alkem Laboratories
5,656.50
(-1.12%)
Aurobindo Pharma
1,121.70
(-1.75%)